(Q38456515)

3 September 2017

Complex correlates of protection after vaccination (English)

1 reference

3 September 2017

1

Stanley A Plotkin

1 reference

PubMed ID

23386629

3 September 2017

language of work or name

English

0 references

publication date

5 February 2013

1 reference

Clinical Infectious Diseases

3 September 2017

1 reference

3 September 2017

56

1 reference

3 September 2017

10

1 reference

3 September 2017

1458-1465

1 reference

Key concepts in immunology

3 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immunological mechanisms of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Follicular helper CD4 T cells (TFH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immunologic correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

A framework for assessing immunological correlates of protection in vaccine trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Correlates of immunity for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Adjuvanted influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Influenza A virus-specific CD8 T-cell responses: from induction to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Influenza vaccine responses in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immune responses to influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Crucial role of antibodies to pertactin in Bordetella pertussis immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

How to make sense of pertussis immunogenicity data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

The role of Toll-like receptor-4 in pertussis vaccine-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Cellular immunity in adolescents and adults following acellular pertussis vaccine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Waning protection after fifth dose of acellular pertussis vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Development of improved vaccines against whooping cough: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antiviral immunity following smallpox virus infection: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Smallpox vaccines: targets of protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine-acquired rotavirus in infants with severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immunity and correlates of protection for rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Influence of potential protective mechanisms on the development of live rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immune responses to rotavirus infection and vaccination and associated correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Rotavirus immune responses and correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Ebolavirus vaccines for humans and apes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Neutralizing antibodies and control of HIV: moves and countermoves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Vaccine-induced CD8+ T cells control AIDS virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Nomenclature for immune correlates of protection after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

CD8+ T cell efficacy in vaccination and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT048

21 January 2018

Identifiers

DOI

10.1093/CID/CIT048

1 reference

3 September 2017

1 reference

PubMed ID

23386629